Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Phase 3positiveVYD2311Positive

AI Analysis

Summary

Invivyd announced positive topline results from the LIBERTY Phase 3 study showing VYD2311 demonstrated superior safety and tolerability compared to mRNA-based COVID-19 vaccines. The company plans to submit VYD2311 for regulatory approval.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

VYD2311 demonstrated safety and tolerability superior to mRNA-based COVID-19 vaccine in LIBERTY Phase 3 study

Importance:7/10

Sentiment:

0.75

Phase 3COVID-19SafetyTolerabilityClinical TrialRegulatory Submission

Related Companies

$IVVD

Read the original article

Published by yahoo_finance on September 29, 2026 11:01 AM

Read Original